Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.
A nationwide study aimed to identify the extended-spectrum beta-lactamases (ESBLs), metallo-beta-lactamases (MBLs), and extended-spectrum oxacillinases (ES-OXAs) in a French collection of 140 clinical Pseudomonas aeruginosa isolates highly resistant to ceftazidime. Six ESBLs (PER-1, n=3; SHV-2a, n=2; VEB-1a, n=1), four MBLs (VIM-2, n=3; IMP-18, n=1), and five ES-OXAs (OXA-19, n=4; OXA-28, n=1) were identified in 13 isolates (9.3% of the collection). The prevalence of these enzymes is still low in French clinical P. aeruginosa isolates but deserves to be closely monitored.
Hocquet
Didier
D
Centre National de Référence de la Résistance aux Antibiotiques, Laboratoire associé P. aeruginosa, Hôpital Jean Minjoz, Besançon, France. dhocquet@univ-fcomte.fr
Plésiat
Patrick
P
Dehecq
Barbara
B
Mariotte
Pierre
P
Talon
Daniel
D
Bertrand
Xavier
X
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002442:Ceftazidime / Q000494:pharmacology*; D018550:Cephalosporin Resistance; D005602:France / Q000453:epidemiology; D006801:Humans; D008826:Microbial Sensitivity Tests; D015995:Prevalence; D011552:Pseudomonas Infections / Q000453:epidemiology* / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000201:enzymology* / Q000235:genetics; D001618:beta-Lactamases / Q000096:biosynthesis / Q000235:genetics*
D000900:Anti-Bacterial Agents; D002442:Ceftazidime; D001618:beta-Lactamases; C108449:oxacillinase